Today, the CFO & Treasurer of SAGE Therapeutics, Kimi Iguchi, exercised options of SAGE Therapeutics (NASDAQ: SAGE) for $360.
Following Kimi Iguchi’s last SAGE Buy transaction on January 07, 2016, the stock climbed by 115.7%. This recent transaction increases Kimi Iguchi’s holding in the company by 3.07% to a total of $4.35 million.
See today’s analyst top recommended stocks >>
Currently, SAGE Therapeutics has an average volume of 511.5K.
Starting in September 2017, SAGE received 60 Buy ratings in a row. 17 different firms, including BMO Capital and Merrill Lynch, currently also have a Buy rating on the stock. Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $213.00, reflecting a -23.5% downside.
The insider sentiment on SAGE Therapeutics has been negative according to 12 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Kimi Iguchi’s trades have generated a 94.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
